投资目标
本基金旨在提供长期资本增长。
更多
本基金将其资产至少80％投资于具增长潜力和以生命科学为导向的公司的股票。基金可投资于任何国家的任何规模的公司。
隐藏内容
关于本基金
- 拟投资于解决庞大医疗需求或寻求提升医疗体系效率的公司
- 旨在建构涵盖行业内各个子类别（生物科技、健康护理服务、医疗器材和制药）的均衡投资组合
- 投资团队由经验丰富的专家组成，致力了解健康护理行业的科学和业务
概述
| 资产类别 | 股票 |
| 产品结构 | Irish Investment Company |
| Currency | 第八条 |
| 成立日期 | 31 Mar 2000 |
| 基本货币 | USD |
|
Fund Assets As of 31/12/24 |
3.79B |
| 行业 | Morningstar Sector Equity Healthcare |
| 基准 | MSCI World Health Care Index |
| 年结日 | 31-Dec |
Portfolio Management
表现
累积表现 (%)
截至2024/11/30
截至2024/11/30
A2 USD (Net)
MSCI World Health Care NR
| 累积 | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1个月 | 3个月 | 6个月 | 年初至今 | 1 年 | 3年 | 5年 |
成立至今 2000/03/31 |
|
| A2 USD (Net) | -0.80 | -6.67 | 3.57 | 10.19 | 18.36 | 18.36 | 49.33 | 457.00 |
| MSCI World Health Care NR | -0.87 | -8.47 | 1.61 | 7.68 | 12.45 | 13.46 | 48.62 | 506.16 |
年度回报(%)
截至2024/09/30
截至2024/09/30
A2 USD (Net)
MSCI World Health Care NR
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| A2 USD (Net) | 5.44 | -4.35 | 4.72 | 23.41 | 27.06 |
| MSCI World Health Care NR | 3.76 | -5.41 | 19.80 | 13.52 | 23.24 |
Recommended holding period 5 Years
Example Investment: USD 10,000
| Scenarios | If you exit after 1 year | If you exit after 5 years | |
|---|---|---|---|
| Minimum | There is no minimum guaranteed return. You could lose some or all of your investment | ||
| Stress | What you might get back after costs | 1,360 USD | 1,420 USD |
| Average return each year | -86.38% | -32.35% | |
| Unfavourable | What you might get back after costs | 7,630 USD | 9,050 USD |
| Average return each year | -23.73% | -1.99% | |
| Moderate | What you might get back after costs | 10,700 USD | 15,060 USD |
| Average return each year | 6.96% | 8.54% | |
| Favourable | What you might get back after costs | 15,230 USD | 21,200 USD |
| Average return each year | 52.26% | 16.22% | |
Fee Information
| 首次认购费 | 5.00% |
| 年度费用 | 1.50% |
| Ongoing Charge (As of 2023/12/31) |
2.38% |
投资组合
最大持仓
(截至2024/11/30)
| 基金的百分比 | |
| Eli Lilly & Co | 8.51 |
| UnitedHealth Group Inc | 7.36 |
| Novo Nordisk A/S | 4.29 |
| AstraZeneca PLC | 3.50 |
| Amgen Inc | 3.00 |
| Johnson & Johnson | 2.96 |
| Abbott Laboratories | 2.67 |
| Boston Scientific Corp | 2.65 |
| Vertex Pharmaceuticals Inc | 2.53 |
| Sanofi SA | 2.52 |
| TOTAL | 39.99 |
| 行业配置 | 基金的百分比 | % of Index | 基金的百分比 | % of Index | As of 2024/11/30 |
| Regional Allocation | 基金的百分比 | % of Index | 基金的百分比 | % of Index | As of November 30, 2024 |
文件
相关研究观点
Our intellectual capital is readily available and central to our Knowledge Shared approach"
2024年10月3日
经济前景黯淡，难挡健康护理股绽放光彩(只提供英文版本)
The sector’s traditionally defensive qualities and accelerating innovation could stand out amid a potentially slowing economy.
